Staphylococcus aureus News and Research

RSS

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.

Atomic layer deposition technique for incorporating "biological functionality" into complex nanomaterials

A team led by researchers from North Carolina State University has published a paper that describes the use of a technique called atomic layer deposition to incorporate "biological functionality" into complex nanomaterials, which could lead to a new generation of medical and environmental health applications. For example, the researchers show how the technology can be used to develop effective, low-cost water purification devices that could be used in developing countries.

23 Mar 2010

Infections from Clostridium difficile on the rise in community hospitals

While prevention methods appear to be helping to lower hospital infection rates from MRSA, a deadly antibiotic-resistant bacterium, a new superbug is on the rise, according to research from the Duke Infection Control Outreach Network.

23 Mar 2010

HAIs in southeast U.S. community hospitals: Infection rates for CDI surpass MRSA's

Researchers studying epidemiology of healthcare-associated infections in community hospitals in the southeast U.S. found that rates of Clostridium difficile infections (CDI) surpassed infection rates for methicillin-resistant Staphylococcus aureus (MRSA). Scientists also discovered that healthcare-associated CDI, which is a bacterium that causes diarrhea and more serious intestinal conditions such as colitis, occurs more often (21 percent) than healthcare-associated infections due to MRSA.

22 Mar 2010

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma Incorporated today announced the presentation of two abstracts relating to Cinryze™ (C1 esterase inhibitor [human]) therapy at the First International Congress of the Southern European Allergy Society in Florence, Italy.

19 Mar 2010

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

ViroPharma Incorporated today announced the launch of 'Ryze Above' (www.ryzeabove.com), an exclusive patient resources program within the company's patient support program, CINRYZESolutions®. The Ryze Above program was created for HAE patients prescribed Cinryze, the first and only drug specifically approved to help prevent swelling and/or painful attacks in teenagers and adults with HAE.

19 Mar 2010

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that a therapy's effect on overall clinical success is the attribute that most influences surveyed infectious disease specialists' prescribing decisions in the treatment of complicated skin and skin structure infections (cSSSIs).

19 Mar 2010

Implementation of evidenced-based practices reduces all healthcare-associated MRSA infections

Scientists at The Virginia Commonwealth University Medical Center found that an emphasis on compliance with non-pathogen specific infection control practices such as hand hygiene, efforts to reduce device-related infections and chlorhexidine bathing (a daily bath with the same antibacterial agent used by surgeons to "scrub in" before an operation), is successful in reducing rates of healthcare-associated methicillin-resistant Staphylococcus aureus.

19 Mar 2010

IDSA calls for global commitment to develop 10 new antibiotics by 2020

As the deaths and suffering caused by antibiotic-resistant bacterial infections continue to rise around the world, the Infectious Diseases Society of America (IDSA) is urging a global commitment to develop 10 new antibiotics by 2020, known as the 10 x '20 initiative, to address this public health crisis and safeguard patients' health.

17 Mar 2010

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

MicuRx Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing next-generation antibiotics, today announced that it has filed an Investigational New Drug (IND) application with the State Food and Drug Administration (SFDA) in China for MRX-I, its first development-stage antibiotic drug candidate. MRX-I, an orally-administered oxazolidinone, targets multi-drug resistant Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

15 Mar 2010

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

TaiGen Biotechnology Co., Ltd. announced today the Phase II trial of nemonoxacin (TG-873870) in Diabetic Foot Infection (DFI) with once-a-day dosing met the primary endpoints and showed promising clinical efficacy and good tolerability.

12 Mar 2010

Antibacterial activity of clay minerals raises hope for natural approaches to antibacterial cures

Alternative approaches to medicine are stock-in-trade in the ASU laboratory of microbiologist Shelley Haydel.

6 Mar 2010

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

MicroPhage announced that it has submitted human data from a pivotal clinical study of its ‘Microphage MRSA/MSSA Blood Culture Test’ to support a U.S. Food and Drug Administration (FDA) 510(k) premarket notification process. The first of MicroPhage’s instrument-free, rapid tests is based on the Company’s patented Bacteriophage Amplification platform technology. MicroPhage further announced that it has already begun OUS commercial shipments of the test.

5 Mar 2010

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Merck & Co., Inc. today announced its updated, newly integrated, late-stage pipeline following its recent merger with Schering-Plough. The new pipeline features a broad and diversified portfolio of investigational medicines and vaccines, including more than 20 candidates in Phase III or under regulatory review, and more than 20 candidates in Phase II of development.

3 Mar 2010

Intercell AG's revenues for full year 2009 increase 10.6%

Today, the biotech-vaccine company Intercell AG announced its financial results for Q4 and the preliminary results for the full financial year 2009, and presented an update on the Company's development programs.

2 Mar 2010

ViroPharma reports 76% growth in fourth-quarter net product sales

ViroPharma Incorporated reported today its financial results for the fourth quarter and year ended December 31, 2009.

24 Feb 2010

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that delays in the U.S. approval and launch of Theravance/Astellas's Vibativ (telavancin) for the treatment of nosocomial pneumonia will reduce by more than half the commercial impact that it was previously forecasted to garner in the methicillin-resistant Staphylococcus aureus (MRSA) drug market.

19 Feb 2010

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Multidrug resistant bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) pose a major problem for patients, doctors, and the pharmaceutical industry. To combat such bacteria, it is critical to understand how resistance is developed in the first place. It is commonly thought that an incomplete course of antibiotics would lead to resistance to that particular antibiotic by allowing the bacteria to make adaptive changes under less stringent conditions.

12 Feb 2010

Excelimmune receives $1M investment as part of open Series-B financing round

Excelimmune, Inc. announced today they have received a $1 million investment as part of an open Series-B financing round. The investment comes from a mixture of existing and new investors.

11 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Eating reptile meat can cause varying degrees of illness

Reptiles are bred in captivity primarily for their skins, but some restaurants and population groups also want them for their meat. A study shows that eating these animals can have side effects that call into question the wisdom of eating this 'delicacy.'

10 Feb 2010

Staphylococcus aureus News and Research

Further Reading

Atomic layer deposition technique for incorporating "biological functionality" into complex nanomaterials

Infections from Clostridium difficile on the rise in community hospitals

HAIs in southeast U.S. community hospitals: Infection rates for CDI surpass MRSA's

ViroPharma to present Cinryze data at Southern European Allergy Society congress

ViroPharma launches 'Ryze Above' for patients with HAE enrolled in CINRYZESolutions support program

Bactericidal antibiotic with activity against MRSA for treatment of cSSSIs would earn 25% patient share: Report

Implementation of evidenced-based practices reduces all healthcare-associated MRSA infections

IDSA calls for global commitment to develop 10 new antibiotics by 2020

MicuRx Pharmaceuticals files IND for MRX-I antibiotic drug candidate with Chinese SFDA

TaiGen Biotechnology's nemonoxacin Phase II study in DFI meets primary endpoints

Antibacterial activity of clay minerals raises hope for natural approaches to antibacterial cures

MicroPhage seeks FDA clearance for MRSA/MSSA Blood Culture Test, submits clinical study data

Merck announces updated late-stage pipeline following its recent merger with Schering-Plough

Intercell AG's revenues for full year 2009 increase 10.6%

ViroPharma reports 76% growth in fourth-quarter net product sales

Delay in Vibativ's approval for nosocomial pneumonia to reduce previously forecasted commercial impact

Low doses of antibiotics may serve as active mutagens and lead to multidrug resistance

Excelimmune receives $1M investment as part of open Series-B financing round

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Eating reptile meat can cause varying degrees of illness

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News